Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 36Terminated 3

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1

Conditions

Breast Neoplasms 2Lung Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × enzastaurin × Clear all
NCT00538681 2020-11-05

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Eli Lilly and Company

Phase 2 Terminated
35 enrolled 14 charts
Thoracic

Lung Neoplasms

NCT00536939 2020-09-24

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Eli Lilly and Company

Phase 2 Terminated
2 enrolled 5 charts
Breast

Breast Neoplasms

NCT00437294 2020-08-10

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Eli Lilly and Company

Phase 2 Terminated
86 enrolled 20 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡